Antimicrobial resistance (AMR) is one of the biggest threats to human health and lives. Beside an expected increase of death cases caused by resistant bacterial infections to 10 mio worldwide, AMR will compromise the achievements of modern medicine, impact world economy and social security.
In my presentation, I will summarize the need for point-of-care diagnostics, alternative approaches to treat bacterial infections. Furthermore, the overall challenge of appropriate antibiotic reimbursement, which is a major obstacle in the field, will be discussed.
For successful drug repurposing in the field of AMR, specific requirements in terms of physico-chemical properties and toxicity of compounds need to be met. Strategies to solve these issues will be discussed.